BioVie Inc. (NASDAQ: BIVI) presented the design of its Phase 2 ADDRESS-LC clinical trial at the Keystone Symposia on Long ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE